Want to see PHIO full AI Analyst Report?
Top Page
Phio Pharmaceuticals
(NASDAQ:PHIO)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.00
▼(-14.53% Downside)
Action:Reiterated
Date:09/14/26
The score is primarily constrained by weak financial performance (no revenue, widening TTM losses, and increased operating cash burn), which elevates funding and dilution risk. Technicals also remain negative with the stock trading below key moving averages and soft momentum indicators. Offsetting these, recent corporate milestones around PH-762 and a strengthened board provide some positive upside signal, while valuation is difficult to assess meaningfully due to negative earnings and no stated dividend yield.
Positive Factors
PH-762 clinical advancement
Completing Phase 1b and submitting an FDA meeting request with a defined Phase 2b neoadjuvant plan advances PH-762 toward a larger clinical test. The manufacturing and toxicology timeline creates a concrete development path, supporting program momentum over coming quarters.
Negative Factors
Pre-revenue business model
The absence of product revenue means PHIO has not yet demonstrated commercial demand or an operating revenue base to support research spending. Until a candidate reaches potential commercialization, progress remains dependent on clinical execution and access to external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
PH-762 clinical advancement
Completing Phase 1b and submitting an FDA meeting request with a defined Phase 2b neoadjuvant plan advances PH-762 toward a larger clinical test. The manufacturing and toxicology timeline creates a concrete development path, supporting program momentum over coming quarters.
Read all positive factors
Phio Pharmaceuticals (PHIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.97M
Dividend YieldN/A
Average Volume (3M)166.92K
Price to Earnings (P/E)―
Beta (1Y)1.92
Revenue GrowthN/A
EPS Growth59.81%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.34
Shares Outstanding11,617,250
10 Day Avg. Volume115,938
30 Day Avg. Volume166,917
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.79
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.00Price Target Upside1096.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Phio Pharmaceuticals Business Overview & Revenue Model
Company Description
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-cen...
How the Company Makes Money
Phio Pharmaceuticals is a clinical-stage company and does not have a product portfolio marketed for commercial sale; therefore, recurring product revenue from drug sales is null. Its ability to generate revenue, when it occurs, is typically tied t...
Phio Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.66M | -4.62M | -3.64M | -6.33M | -7.01M | -8.89M |
| EBITDA | -13.03M | -8.70M | -7.15M | -10.64M | -11.41M | -13.21M |
| Net Income | -12.90M | -8.70M | -7.15M | -10.83M | -11.48M | -13.29M |
Balance Sheet | ||||||
| Total Assets | 14.31M | 21.49M | 5.74M | 9.36M | 12.81M | 25.17M |
| Cash, Cash Equivalents and Short-Term Investments | 13.00M | 21.03M | 5.38M | 8.49M | 11.78M | 24.06M |
| Total Debt | 0.00 | 0.00 | 0.00 | 35.00K | 170.00K | 295.00K |
| Total Liabilities | 1.71M | 1.34M | 1.01M | 1.63M | 1.97M | 3.24M |
| Stockholders Equity | 12.60M | 20.15M | 4.72M | 7.73M | 10.84M | 21.93M |
Cash Flow | ||||||
| Free Cash Flow | -12.21M | -7.99M | -7.11M | -10.75M | -12.25M | -11.91M |
| Operating Cash Flow | -12.20M | -7.98M | -7.11M | -10.75M | -12.13M | -11.86M |
| Investing Cash Flow | -4.00K | -12.00K | 8.00K | -5.00K | -121.00K | -51.00K |
| Financing Cash Flow | 14.43M | 23.64M | 4.00M | 7.41M | -26.00K | 21.72M |
Phio Pharmaceuticals Technical Analysis
Neutral
1.17
Price Trends
1.06
Negative
1.06
Negative
1.11
Negative
Market Momentum
-0.02
Negative
47.00
Neutral
50.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHIO, the sentiment is Neutral. The current price of 1.17 is above the 20-day moving average (MA) of 1.03, above the 50-day MA of 1.06, and above the 200-day MA of 1.11, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.00 is Neutral, neither overbought nor oversold. The STOCH value of 50.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PHIO.
Phio Pharmaceuticals Risk Analysis
Phio Pharmaceuticals disclosed 23 risk factors in its most recent earnings report. Phio Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Phio Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $14.90M | -0.40 | -218.59% | ― | ― | 38.14% | |
46 Neutral | $11.97M | -0.77 | -87.41% | ― | ― | 59.81% | |
46 Neutral | $12.77M | -0.71 | -91.18% | ― | ― | 81.87% | |
42 Neutral | $9.73M | >-0.01 | -222.32% | ― | ― | 78.25% | |
41 Neutral | $7.46M | -0.91 | -237.91% | ― | ― | 23.05% | |
41 Neutral | $9.58M | -0.18 | -1539.97% | ― | ― | 80.28% |
* Healthcare Sector Average
PHIO
Phio Pharmaceuticals
1.00
-1.39
-58.16%
KALA
KALA BIO
0.42
-76.58
-99.46%
XCUR
Exicure
1.18
-3.00
-71.77%
PASG
Passage Bio
4.20
-3.85
-47.81%
INAB
IN8bio
1.40
-0.89
-38.86%
SNTI
Senti Biosciences
0.32
-1.20
-78.68%
Phio Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Phio Advances PH-762 Toward Phase 2b Skin Cancer Trial
Positive
Sep 14, 2026
On September 14, 2026, Phio Pharmaceuticals announced a key development milestone for its lead candidate PH-762 following formal completion of a Phase 1b trial in skin cancers. The company submitted a meeting request and comprehensive briefing pac...
Business Operations and StrategyExecutive/Board Changes
Phio Pharmaceuticals adds dermatology expert to board
Positive
Jul 21, 2026
Effective July 20, 2026, Phio Pharmaceuticals increased its Board of Directors to six members and appointed dermatologist and clinical researcher R. Todd Plott, M.D. as a director and Governance Committee member through the 2026 annual meeting. Pl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.